Anti-GD2 immunotherapy for neuroblastomas - PMC - PubMed …
Anti-GD2 monoclonal antibodies are associated with improved survival in patients in their first remission and are increasingly being used for chemorefractory and relapsed neuroblastoma. As protein engineering technology has become more accessible, newer antibody constructs are …
Anti-GD2 synergizes with CD47 blockade to mediate tumor …
2022年1月13日 · Anti-GD2 antibodies block the interaction of GD2 with Siglec-7 and therapeutically disrupt its inhibitory effects on the immune system.
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin …
2010年9月30日 · A chimeric human–murine anti-GD2 monoclonal antibody 8 called ch14.18 has shown activity against neuroblastoma in preclinical studies 9 and early-phase clinical trials 10,11; this activity...
Anti-GD2 Antibody Therapy for GD2-expressing Tumors - PMC
Anti-GD2 antibodies have shown promising anti-tumor activity in adult and pediatric patients with GD2-expressing tumors, primarily neuroblastoma and melanoma.
Intravenous and intracranial GD2-CAR T cells for H3K27M
2 天之前 · Flow cytometry (FACS) for GD2-CAR, using an anti-idiotype antibody (clone 1A7), demonstrated presence of GD2-CAR T cells (threshold of detection > 0.1% GD2-CART of CD3% T cells) in patient CSF ...
GD2-targeting therapy: a comparative analysis of approaches and ...
2024年2月26日 · Internalization of anti-GD2 antibodies can provide a means to deliver drugs or toxins directly into the tumor cell. However, it can also be a mechanism for tumors to evade immunotherapy with naked mAbs.
Advances in Anti-GD2 Immunotherapy for Treatment of High-Risk ...
Development of human anti-chimeric antibody (HACA), human anti-mouse antibody (HAMA), and human anti-human antibody (HAHA) can be a mechanism of resistance to tumor immunotherapy with anti-GD2 mAb.
Disialoganglioside GD2 Expression in Solid Tumors and Role as a …
2020年7月7日 · Anti-GD2 monoclonal antibodies target GD2-expressing tumor cells, leading to phagocytosis and destruction by means of antibody-dependent cell-mediated cytotoxicity, lysis by complement-dependent cytotoxicity, and apoptosis and necrosis through direct induction of …
Advancing therapy for neuroblastoma | Nature Reviews Clinical …
2022年5月25日 · Anti-GD2 antibodies have intrinsic antitumour activity, enhance NK cell-dependent antibody-dependent cell mediated cytotoxicity, and promote tumour cell phagocytosis.
GD2 - Wikipedia
The chimeric (murine-human) anti-GD2 monoclonal antibody ch14.18 is FDA-approved for the treatment of pediatric patients with high-risk neuroblastoma and has been studied in patients with other GD2-expressing tumors.